Nycomed Amersham set to expand core imaging business
This article was originally published in Clinica
Executive Summary
Imaging giant Nycomed Amersham is poised to make an acquisition following the sale of its pharmaceuticals business in a £340 million transaction ($555 million). The company will use the money to reduce debt and to expand its more profitable core businesses - imaging and life sciences.